Clerkenwell Health is a transformative brand that is revolutionizing clinical development. With a team of dedicated experts, we are committed to supporting patients, corporates, and therapists in their healthcare journey. Our story began long before 2021, with founders who have years of experience in the field.

Co-founder Dr. Henry Fisher has a background in psychedelic science, having worked at renowned organizations like The Beckley Foundation and Volteface. Teaming up with Tom McDonald, an expert in patient-centric care and clinical data, they envisioned a mental health startup that prioritizes patients above all else.

Since our launch in early 2021, we have made significant progress. We have assembled a team of clinical, psychiatric, and psychedelic specialists who can support our clients' trial design and delivery. Furthermore, 2021 saw positive developments in the policy landscape, with the UK government creating a more globally competitive framework for clinical trials.

We have already been granted an Innovation Passport for DMT-assisted therapy for Major Depressive Disorder. In 2022, we reached major milestones, solidifying our position as a leading player in the field. We opened Europe's first commercial research site dedicated to psychedelic trials and signed additional clients.

Moving forward, we anticipate several key trends in 2023 and beyond, including the strengthening of the commercial research infrastructure in the UK, the mainstreaming of psychedelics, and the focus on the broader components of psychedelic-assisted therapies. Join us at Clerkenwell Health as we continue to drive innovation and make a positive impact on the future of healthcare